Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers

To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.

Inclusion Criteria:

• Healthy males, 20 to 45 years of age the moment of screening
• Body mass index is between 18.0 and 30.0 kg/m

Exclusion Criteria:

• The tuberculosis patient or latent tuberculosis patient
• Hypersensitivity response to the test and comparator drugs